ALK and lung adenocarcinoma: For example, mutations of KRAS and NRAS predict resistance to anti-EGFR antibodies in colorectal cancers, and patients with lung adenocarcinoma that harbor EGFR mutations or ALK rearrangements have shown remarkable efficacy in relevant targeted drug therapy (21, 22).